WHAT WE’RE READING – JOURNAL CLUB

Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke

DOI: 10.1056/NEJMoa1705915

Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale

DOI: 10.1056/NEJMoa1009639

Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism

DOI: 10.1056/NEJMoa1211716

Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke

DOI: 10.1056/NEJMoa1707404

Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke

DOI: 10.1056/NEJMoa1301440

Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke

DOI: 10.1056/NEJMoa1610057

WHAT WE’RE READING – JOURNAL CLUB

Efficacy and safety of endovascular thrombectomy in mild ischemic stroke: results from a retrospective study and meta-analysis of previous trials

doi.org/10.1186/s12883-019-1372-9

Mechanical Thrombectomy for Minor and Mild Stroke Patients Harboring Large Vessel Occlusion in the Anterior Circulation

https://doi.org/10.1161/STROKEAHA.117.018113
Stroke. 2017;48:3274–3281

Endovascular Thrombectomy for Mild Strokes: How Low Should We Go?

doi.org/10.1161/STROKEAHA.118.022114
Stroke. 2018;49:2398–2405

Mechanical Thrombectomy in Patients With Milder Strokes and Large Vessel Occlusions

doi.org/10.1161/STROKEAHA.118.021106
Stroke. 2018;49:2391–2397

WHAT WE’RE READING – JOURNAL CLUB

Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques

https://doi.org/10.1161/STROKEAHA.113.004251

Apixaban versus Warfarin in Patients with Atrial Fibrillation

DOI: 10.1056/NEJMoa1107039

Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation

An Individual Patient Meta-analysis
DOI:10.1001/jama.288.19.2441

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

DOI: 10.1056/NEJMoa0905561

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

DOI: 10.1056/NEJMoa1009638

Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm

DOI: 10.1056/NEJMoa1202299

What We’re Reading – Journal Club

ATLANTIS Trial

Results for Patients Treated Within 3 Hours of Stroke Onset
DOI: 10.1161 AHA Stroke. 2002;33:493–496

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

N Engl J Med 2008; 359:1317-1329
DOI: 10.1056/NEJMoa0804656

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

https://doi.org/10.1016/S0140-6736(12)60768-5

TISSUE PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE

THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE rt-PA STROKE STUDY GROUP
DOI: 10.1056/NEJM199512143332401